Danaher Corporation (DHR)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Danaher Corporation (DHR) trades at $197.93 with AI Score 69/100 (Grade B+). Danaher Corporation is a global science and technology innovator focused on solving complex challenges in life sciences, diagnostics, and environmental & applied solutions. Market cap: $140.09B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026DHR stock analysis for 2026: Analysts have set a consensus price target of $257.50 for Danaher Corporation, suggesting 30.1% upside from the current price of $197.93. The AI MoonshotScore is 69/100, indicating a bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
DHR: 1/1 perspectives are bullish.
How is this calculated? →Danaher Corporation (DHR) Healthcare & Pipeline Overview
Danaher Corporation is a diversified science and technology company providing innovative solutions in life sciences, diagnostics, and environmental & applied solutions. With a focus on high-growth markets and a disciplined acquisition strategy, Danaher leverages its proprietary Danaher Business System to drive operational efficiencies and market leadership.
What Is the Investment Thesis for DHR?
Danaher Corporation presents a notable research candidate due to its diversified business model, strong market positions, and consistent execution through the Danaher Business System. With a market capitalization of $140.09B and a profit margin of 14.9%, Danaher demonstrates financial stability and profitability. Key value drivers include continued growth in the life sciences and diagnostics segments, driven by increasing demand for advanced healthcare solutions. The company's disciplined acquisition strategy and focus on operational efficiencies are expected to further enhance profitability and shareholder value. The dividend yield of 0.79% provides a modest income stream, while potential risks include regulatory changes and economic slowdowns impacting healthcare spending.
Based on FMP financials and quantitative analysis
DHR Key Highlights
- Market Cap of $140.09B reflects Danaher's strong market position and investor confidence.
- P/E ratio of 36.6 indicates a premium valuation, reflecting expectations of future growth.
- Gross Margin of 60.7% demonstrates efficient operations and strong pricing power.
- Profit Margin of 14.9% showcases Danaher's ability to convert revenue into profit.
- Beta of 0.99 suggests that Danaher's stock price is slightly less volatile than the overall market.
Who Are DHR's Competitors?
DHR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $374.15 | +3.55% | $201.93B | 83 |
| GILD Gilead Sciences, Inc. | $131.27 | +4.21% | $162.98B | 94 |
| ISRG Intuitive Surgical, Inc. | $426.01 | +5.87% | $150.88B | 96 |
| PFE Pfizer Inc. | $24.32 | +1.84% | $138.61B | 64 |
| SNY Sanofi | $43.16 | +3.68% | $103.77B | 58 |
| PRE Prenetics Global Limited | $16.93 | -5.37% | $287.82M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| TWST Twist Bioscience Corporation | $99.24 | -2.94% | $6.18B | 65 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DHR's Key Strengths?
- Diversified business model with exposure to multiple high-growth markets.
- Strong market positions in life sciences, diagnostics, and environmental solutions.
- Proprietary Danaher Business System (DBS) drives continuous improvement and operational excellence.
- Proven track record of successful acquisitions.
What Are DHR's Weaknesses?
- Exposure to regulatory changes and healthcare spending trends.
- Dependence on innovation and technological advancements.
- Integration risks associated with acquisitions.
- Potential for economic slowdowns to impact demand.
What Could Drive DHR Stock Higher?
- Continued implementation of the Danaher Business System (DBS) across all segments to drive operational efficiencies and margin expansion.
- Strategic acquisitions to expand product portfolio and market reach in high-growth areas.
- New product launches and technological advancements in genomics, diagnostics, and environmental solutions.
- Expansion in emerging markets with growing healthcare needs and increasing demand for water quality solutions.
What Are the Key Risks for DHR?
- Rich valuation — a P/E of 36.6 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Regulatory changes and healthcare spending trends impacting demand for Danaher's products and services.
- Integration risks associated with acquisitions and the potential for disruptions to business operations.
- Competition from other large healthcare and industrial companies.
- Economic downturns and global health crises impacting demand and supply chains.
What Are the Growth Opportunities for DHR?
- Expansion in Genomics and Bioprocessing: Danaher can capitalize on the rapidly growing genomics and bioprocessing markets. The global genomics market is projected to reach $55.4 billion by 2028, driven by advancements in DNA sequencing and personalized medicine. Danaher's Life Sciences segment, with its strong portfolio of genomics consumables and bioprocess technologies, is well-positioned to capture a significant share of this market. Investing in R&D and strategic acquisitions in this area will be crucial for sustained growth.
- Increasing Demand for Diagnostics Solutions: The global diagnostics market is expected to grow, driven by the increasing prevalence of chronic diseases and the need for early and accurate diagnosis. Danaher's Diagnostics segment offers a comprehensive range of clinical instruments, reagents, and software for hospitals, laboratories, and physicians' offices. Expanding its presence in emerging markets and developing innovative diagnostic solutions will be key to capturing this growth opportunity. The market is projected to reach $127.78 billion by 2029.
- Water Quality and Treatment Solutions: With increasing concerns about water scarcity and pollution, the demand for water quality and treatment solutions is growing. Danaher's Environmental & Applied Solutions segment provides instrumentation, software, and services for water analysis and treatment. Expanding its product offerings and geographic reach in this area will be crucial for capturing this growth opportunity. The global water and wastewater treatment market is projected to reach $220 billion by 2025.
- Danaher Business System (DBS) Implementation: Danaher's proprietary Danaher Business System (DBS) is a key competitive advantage that drives continuous improvement and operational excellence across its businesses. Expanding the implementation of DBS across all segments and newly acquired companies will further enhance profitability and efficiency. This ongoing process optimization will contribute to sustained growth and shareholder value.
- Strategic Acquisitions: Danaher has a proven track record of successful acquisitions that have expanded its product portfolio and market reach. Continuing to pursue strategic acquisitions in high-growth areas, such as genomics, diagnostics, and environmental solutions, will be crucial for sustained growth. A disciplined approach to acquisitions, with a focus on companies that align with Danaher's strategic priorities and can benefit from DBS, will be essential.
What Opportunities Does DHR Have?
- Expansion in emerging markets with growing healthcare needs.
- Increasing demand for genomics, diagnostics, and environmental solutions.
- Strategic acquisitions to expand product portfolio and market reach.
- Continued implementation of DBS to drive operational efficiencies.
What Threats Does DHR Face?
- Competition from other large healthcare and industrial companies.
- Pricing pressures and reimbursement challenges.
- Product liability and regulatory risks.
- Economic downturns and global health crises.
What Are DHR's Competitive Advantages?
- Proprietary Danaher Business System (DBS) drives continuous improvement and operational excellence.
- Diversified portfolio of leading brands with strong market positions.
- Strategic acquisition strategy expands product portfolio and market reach.
- Focus on high-growth markets, such as genomics, diagnostics, and environmental solutions.
What Does DHR Do?
Danaher Corporation, founded in 1969 and headquartered in Washington, D.C., has evolved from Diversified Mortgage Investors, Inc. into a global leader in science and technology. The company operates through three primary segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of products including mass spectrometers, flow cytometry systems, microscopes, and genomic consumables, serving pharmaceutical, biopharmaceutical, and research institutions. The Diagnostics segment provides clinical instruments, reagents, and software for hospitals, laboratories, and physicians' offices, focusing on chemistry, immunoassay, and molecular diagnostics. The Environmental & Applied Solutions segment delivers instrumentation, software, and services for water quality analysis and treatment, as well as packaging and color management solutions for various industries. Danaher's success is underpinned by the Danaher Business System (DBS), a proprietary set of tools and processes that drive continuous improvement and operational excellence across its businesses. Through strategic acquisitions and organic growth, Danaher has built a diversified portfolio of leading brands, each focused on delivering innovative solutions to its customers.
What Products and Services Does DHR Offer?
- Develops and manufactures professional, medical, industrial, and commercial products.
- Offers solutions for life sciences research, including genomics, proteomics, and cell biology.
- Provides diagnostic instruments, reagents, and software for clinical laboratories and healthcare providers.
- Delivers water quality analysis and treatment solutions for residential, commercial, and industrial applications.
- Offers packaging and color management solutions for consumer, pharmaceutical, and industrial products.
- Serves customers worldwide through a diversified portfolio of leading brands.
How Does DHR Make Money?
- Develops and manufactures a wide range of products and services across three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions.
- Generates revenue through the sale of instruments, reagents, consumables, software, and services.
- Utilizes the Danaher Business System (DBS) to drive continuous improvement and operational excellence.
- Pursues strategic acquisitions to expand its product portfolio and market reach.
What Industry Does DHR Operate In?
Danaher operates in the healthcare and industrial sectors, which are characterized by continuous innovation and increasing demand for advanced technologies. The global diagnostics market is expected to grow, driven by the increasing prevalence of chronic diseases and the need for early and accurate diagnosis. The life sciences sector is also experiencing growth, fueled by advancements in genomics, proteomics, and cell biology. Danaher's diversified portfolio and strong market positions enable it to capitalize on these trends, while competition from companies like Amgen Inc. (AMGN) and Pfizer Inc. (PFE) requires continuous innovation and operational excellence.
Who Are DHR's Key Customers?
- Pharmaceutical and biopharmaceutical companies.
- Hospitals, physicians' offices, and reference laboratories.
- Universities, medical schools, and research institutions.
- Various industrial manufacturers.
- Residential and commercial customers requiring water quality solutions.
How Danaher Corporation Is Valued
Danaher Corporation carries a market capitalization of $140.09B, placing it in the large-cap category. Relative to its peer group, DHR's quantitative score of 69/100 is roughly in line with the peer average of 79/100.
ROE 7%Key Financial Metrics
Return on equity for Danaher Corporation stands at 7.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.4%, showing how much profit it generates from its asset base. DHR trades at a trailing price-to-earnings ratio of 36.55, above the Healthcare sector average of ~23x. Its free cash flow yield is 3.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.87 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
Danaher Corporation's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.12 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Danaher Corporation revenue of about $25.54B for fiscal 2026, with EPS near $8.44. The estimate reflects 5 contributing analysts.
Net buyingInsider Activity
Over the past six months, Danaher Corporation insiders filed 30 SEC Form 4 transactions — 3 sales and 27 purchases. On net that is roughly 33K shares acquired (about $3.3M) — insiders putting money in tends to read as conviction.
DHR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Danaher's growth trajectory, indicating that key executives believe in the company's future prospects.
- Community sentiment has shifted positively, with discussions highlighting Danaher's strong portfolio in life sciences and diagnostics, which are critical sectors.
- Analysts are optimistic about Danaher's ability to leverage its innovative technologies, positioning it well against competitors in the healthcare space.
- Market perception is buoyed by recent advancements in product offerings, which have garnered attention and praise from industry experts.
Bear Case
- Despite positive sentiment, some analysts express concerns about potential supply chain disruptions that could impact operational efficiency.
- The market remains cautious due to macroeconomic uncertainties, which could affect healthcare spending and, in turn, Danaher's revenue growth.
- Community discussions reveal skepticism regarding the company's ability to maintain margins amidst rising operational costs in the current economic climate.
- Recent bearish views stem from a perceived overvaluation compared to industry peers, leading to questions about sustainability of current performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
From the Earnings Call
“Additionally, given our strong Q1 performance, we're raising our full year adjusted diluted net EPS guidance to a range of $8.35 to $8.55 versus our previous range of $8.35 to $8.50.”
— Rainer Blair, President and Chief Executive Officer
“For the full year 2026, there is no change to our expectation of core revenue growth in the 3% to 6% range.”
— Rainer Blair, President and Chief Executive Officer
DHR Q1 FY2026 earnings call transcript · 2026-04-21
DHR Latest News
-
Danaher Foundation Commits $1 Million to Ebola Outbreak Relief Efforts in Central Africa
prnewswire.com · Jun 29, 2026
-
Danaher (DHR) Completes $9.9B Acquisition of Masimo Corporation
Yahoo! Finance: DHR News · Jun 29, 2026
-
Is Danaher (DHR) One of the Best Non-Tech Stocks to Buy According to Analysts?
Yahoo! Finance: DHR News · Jun 28, 2026
-
3 Mid-Cap Stocks Walking a Fine Line
Yahoo! Finance: DHR News · Jun 26, 2026
DHR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DHR.
Price Targets
Consensus target: $257.50
DHR MoonshotScore
What does this score mean?
The MoonshotScore rates DHR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Danaher Foundation Commits $1 Million to Ebola Outbreak Relief Efforts in Central Africa
Danaher (DHR) Completes $9.9B Acquisition of Masimo Corporation
Is Danaher (DHR) One of the Best Non-Tech Stocks to Buy According to Analysts?
3 Mid-Cap Stocks Walking a Fine Line
Latest Danaher Corporation Analysis
Leadership: Rainer Blair
President and Chief Executive Officer
Rainer Blair serves as the President and Chief Executive Officer of Danaher Corporation. Before assuming this role, he held various leadership positions within Danaher, including Executive Vice President and Group Executive. His extensive experience in the life sciences and diagnostics industries has been instrumental in driving Danaher's growth and innovation. Blair's strategic vision and operational expertise have contributed to the company's success in navigating complex market dynamics and delivering value to shareholders. He is focused on continuing the evolution and impact of the Danaher Business System.
Track Record: Under Rainer Blair's leadership, Danaher has continued to execute its strategic priorities, including driving organic growth, expanding its product portfolio through strategic acquisitions, and enhancing operational efficiencies through the Danaher Business System. He has overseen significant investments in R&D and innovation, positioning Danaher as a leader in the life sciences, diagnostics, and environmental solutions markets. Blair's focus on customer satisfaction and employee engagement has contributed to a positive and productive work environment.
DHR Healthcare Stock FAQ
What does Danaher Corporation do?
Danaher Corporation is a global science and technology innovator that designs, manufactures, and markets a wide range of professional, medical, industrial, and commercial products and services. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. These segments provide solutions for genomics, proteomics, cell biology, clinical diagnostics, water quality analysis, and packaging and color management. Danaher's diversified portfolio and strong market positions enable it to serve a wide range of customers in various industries worldwide.
What do analysts say about DHR stock?
Analysts generally view Danaher Corporation favorably, citing its diversified business model, strong market positions, and consistent execution through the Danaher Business System. Key valuation metrics, such as the P/E ratio of 36.6, reflect expectations of future growth. Analysts also note the company's disciplined acquisition strategy and focus on operational efficiencies as positive factors. However, potential risks, such as regulatory changes and economic slowdowns, are also considered. Analyst consensus typically reflects a positive outlook for Danaher's long-term growth potential.
What are the main risks for DHR?
Danaher Corporation faces several risks, including regulatory changes and healthcare spending trends that could impact demand for its products and services. Integration risks associated with acquisitions and the potential for disruptions to business operations are also a concern. Competition from other large healthcare and industrial companies, as well as pricing pressures and reimbursement challenges, could also affect profitability. Additionally, economic downturns and global health crises could impact demand and supply chains, posing a risk to Danaher's financial performance.
What are the key factors to evaluate for DHR?
Danaher Corporation (DHR) holds an AI score of 69/100 (moderate). P/E: 36.6x vs the S&P 500's ~20-25x. Analysts target $257.50 (+30%). Not financial advice.
How frequently does DHR data refresh on this page?
DHR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DHR's recent stock price performance?
Danaher Corporation (DHR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified business model with exposure to multiple high-growth markets. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DHR overvalued or undervalued right now?
Danaher Corporation (DHR) trades at 36.6x earnings. Analysts target $257.50 (+30%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying DHR?
Before investing in Danaher Corporation (DHR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are as of the latest reporting period.